Ngl Fine-chem Ltd. · NSE:NGLFINE
Ngl Fine-chem — Q4 FY22 Earnings Presentation
19 slides from Ngl Fine-chem's earnings presentation, March 2026
Slide 1: Earnings Presentation Q4 & FY22
Earnings Presentation Q4 & FY22
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by NGL Fine-Chem Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securiti
Slide 3: Q4/FY22 Highlights of the Year
Q4/FY22 Highlights of the Year 3
Slide 4: Year in review
Year in review Business Environment Operations • Demand in key markets remained very strong coupled • 90%+ capacity utilization (excl new Mactrotech expansion) with high customer retention during the year led by strong demand in key markets • Macro factors pushed input costs to new highs during the
Slide 5: Consolidated profit & loss statement
Consolidated profit & loss statement (Rs Cr) Q4FY22 Q4FY21 YoY% FY22 FY21 YoY % Revenue from operations 84.1 71.8 17% 317.5 258.0 23% Cost of material consumed 39.9 26.5 147.0 102.3 Gross Profit 44.1 45.2 -2% 170.5 155.6 10% Gross Profit margin 52% 63% 54% 60% Employee expenses 9.3 7.4 34.9 28.1 Oth
Slide 6: Segment distribution
Segment distribution FY22 Revenue Distribution Revenue (Rs Cr) Q4FY22 Q4FY21 YoY% FY22 FY21 YoY % Human API, 7% Veterinary API 66.2 58.6 13.0% 257.8 204.5 26.0% Intermediates, 9% Finished Dosage Forms 1.1 4.9 -78.3% 7.9 12.2 -35.4% Finished Human API 6.7 6.0 10.5% 20.5 17.7 15.7% Dosage Forms, 3% In
Slide 7: Regional distribution
Regional distribution FY22 Revenue Distribution Revenue (Rs Cr) Q4FY22 Q4FY21 YoY% FY22 FY21 YoY % ROW, 15% Asia Pacific 21.3 19.8 7.7% 93.8 82.0 14.3% India, 24% USA, 3% Europe 23.1 24.0 -3.6% 87.2 80.7 8.0% India 22.2 14.3 55.1% 76.3 57.5 32.8% ROW 11.5 9.5 20.8% 47.2 28.2 67.2% USA - 4.1 - 9.8 6.
Slide 8: Consolidated balance sheet highlights
Consolidated balance sheet highlights Abridged Balance Sheet (Rs Cr) Mar-22 Mar-21 Shareholders' Funds 203 154 ▪ Increased inventories due to new Total Borrowings 27 16 product development and change in Trade Payables 37 30 product mix, with NWC of 92 days as of Mar’22 Other Liabilities 10 8 Total L
Slide 9: Overview, Key Strengths and Strategy
Overview, Key Strengths and Strategy 9
Slide 10: Leading animal health company
Leading animal health company Comprehensive product ▪ 22 APIs (18 veterinary API, 4 human), 4 intermediates, 10 finished dosage forms portfolio ▪ Best quality and value-driven pricing Market leadership in ▪ Leadership in top 3 products – 50%+ market share vet API ▪ Growing position in next 4 – takin
Slide 11: Leadership in veterinary API segment
Leadership in veterinary API segment Strong controls of processes with Wide Range of Product Categories High quality and reliable 95% in-house manufacturing and products with no market rejection Anthelmintics backward integrated facilities in 15 years leading to cost competitiveness Ectoparasiticide
Slide 12: State-of-the-art manufacturing capabilities
State-of-the-art manufacturing capabilities 3 manufacturing facilities located at Tarapur & Navi Mumbai, Maharashtra, designed to meet the requirements of regulatory agencies and are capable of a wide range of reaction capabilities 10,000 m2 102 m3 194 m3 Area of manufacturing Glass-lined reactors S
Slide 13: Advantageously placed in a growing opportunity
Advantageously placed in a growing opportunity Market Size 2020 Market Size 2027 Segment Trends Growth Drivers ▪ Pharma segment to grow ▪ Rising prevalence of at higher rate – 5.4% Animal Health zoonotic diseases, animal $192 Billion CAGR Market $139 Billion (CAGR – 4.7%) population & pet ownership
Slide 14: Strategy for next leg of growth
Strategy for next leg of growth Brownfield Expansion Outsource Production De-bottlenecking Ongoing initiatives to increase capacities to • Completed 26 cr expansion in • Target to outsource production • Continuous debottlenecking & meet growing demand subsidiary Macrotech to 15% by FY24 process impr
Slide 15: Historical Financial Performance
Historical Financial Performance 15
Slide 16: Robust financial performance
Robust financial performance Consolidated Figures Revenue (Rs Cr) EBITDA (Rs Cr) PAT (Rs Cr) 27% CAGR 28% CAGR 35% CAGR 318 80 57 50 258 68 153 152 32 20 19 8 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 Gross Margin (%) EBITDA Margin (%) PAT Margin (%) 59% 58% 60% 54% 31% 21% 21% 22%
Slide 17: Improving efficiencies
Improving efficiencies Consolidated Figures ROCE (%) Debt/ Equity (x) Fixed Asset Turnover (x) 53% 3.4 3.4 0.25 0.23 2.5 34% 2.3 27% 0.13 0.07 12% FY19 FY20 FY21 FY21 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 ROCE = EBIT / Avg Capital Employed (Shareholder’s Fund + Total Debt) Debt/Equity = Total Debt
Slide 18: Consolidated profit & loss statement
Consolidated profit & loss statement (Rs Cr) FY22 FY21 FY20 Revenue from operations 317.5 258.0 151.7 Cost of material consumed 147.0 102.4 64.4 Gross Profit 170.5 155.6 87.3 Gross Profit margin 54% 60.3% 57.5% Employee expenses 34.9 28.1 24.0 Other expenses 67.8 47.8 43.9 EBITDA 67.9 79.7 19.4 EBIT
Slide 19: Thank You
Thank You Pareto Capital (Investor Relations) NGL Fine-Chem Ltd Pooja Dokania Pallavi Pednekar pooja.dokania@paretocapital.in (Company Secretary) cs@nglfinechem.com Rishav Das rishav.das@paretocapital.in 19